RxDoctor Payments Data

Theresa Bryant, PA

Physician Assistant · Fort Worth, TXNPI 1205173424

Payments from drug & device makers

$9,786in general payments, 2019–2025

Across 422 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Pfizer$884
  • AbbVie$860
  • AstraZeneca$796
  • Boehringer Ingelheim$758
  • Lilly USA, LLC$543
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$8008%
  • Travel & lodging$3043%
  • Food & beverage$8,68189%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,786 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$38,036
Medicare patients
136
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$109,858
JardianceEmpagliflozin41$40,634
EliquisApixaban47$38,172
MounjaroTirzepatide25$37,774
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,786
XareltoRivaroxaban20$16,547
Janumet XrSitagliptin Phos/Metformin Hcl13$12,615
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,961
JanuviaSitagliptin Phosphate14$11,780
Rosuvastatin Calcium197$2,252
PremarinEstrogens, Conjugated11$2,243
Omeprazole80$1,520
Gabapentin78$1,483
Atorvastatin Calcium172$1,480
Amlodipine Besylate192$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$419$109,858101 claims
Boehringer IngelheimJardiance$758$40,63441 claims
PfizerEliquis, Premarin$884$40,41658 claims
Lilly USA, LLCMounjaro$543$37,77425 claims
MerckJanumet Xr, Januvia$13$24,39527 claims
GSKTrelegy Ellipta$444$19,78624 claims
AstraZenecaBreztri Aerosphere$796$11,96117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →